INDIVIOR PLC
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
Stock Performance Snapshot
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring INDV
Beyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Published: August 5, 2025
Explore BasketImmersive Rehab & VR Therapy
Virtual and augmented reality are transforming healthcare with innovative digital treatments for physical and psychological healing. These carefully selected companies are at the forefront of creating immersive technologies that offer effective alternatives to traditional therapies, poised to benefit from growing clinical acceptance.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Confirm the issuer
Verify whether INDV is a company, ETF or other instrument and read the prospectus or filings; unclear issuers increase information risk.
Check liquidity & fees
Look at trading volume, bid-ask spreads and any expense ratio for funds — low liquidity and high fees can raise costs and execution risk.
Monitor fundamentals
Review earnings, debt, and sector exposure for companies or holdings and tracking methodology for funds, while remembering returns aren’t guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
